---
id: kdigo-ckd-mbd-2024
title: "KDIGO 2024 Clinical Practice Guideline Update: CKD-Mineral and Bone Disorder"
short_title: "KDIGO CKD-MBD 2024"

organization: Kidney Disease Improving Global Outcomes
collaborators: null
country: Global
url: https://kdigo.org/guidelines/
doi: null
pmid: null
open_access: true

specialty: nephrology
guideline_type: clinical-practice
evidence_system: KDIGO GRADE
conditions:
  - CKD-MBD
  - chronic kidney disease
  - secondary hyperparathyroidism
  - renal osteodystrophy
tags:
  - calcium
  - phosphorus
  - PTH
  - vitamin D
  - calcimimetics

publication_date: 2024-03-01
previous_version_date: 2017-07-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-24
---

## Scope
2024 KDIGO guideline update on the diagnosis and management of chronic kidney disease-mineral and bone disorder (CKD-MBD).

## Key Recommendations

### Monitoring (CKD G3a-G5D)
- **Calcium, Phosphorus**: Monitor every 6-12 months (G3a-G3b), every 3-6 months (G4-G5), every 1-3 months (dialysis).
- **PTH**: Monitor every 6-12 months (G3a-G4), every 3-6 months (G5/G5D).
- **Alkaline Phosphatase**: Annually or with clinical indication.
- **25(OH) Vitamin D**: Measure and correct deficiency.

### Phosphorus Management
- Maintain serum phosphorus toward normal range (avoid severe hyperphosphatemia).
- **Dietary Phosphorus Restriction**: Limit processed foods and phosphate additives.
- **Phosphate Binders**: Use if hyperphosphatemia persists despite diet. Non-calcium binders (sevelamer, lanthanum, iron-based binders) preferred to limit calcium load, especially in patients with vascular calcification or adynamic bone disease.

### Calcium Management
- Avoid hypercalcemia.
- Limit calcium-based phosphate binders.
- Dialysate calcium should be individualized.

### PTH Management
- Prevent severe hyperparathyroidism (PTH markedly elevated >2-9x upper normal for dialysis patients) while avoiding oversuppression (adynamic bone disease).
- **Calcimimetics (Cinacalcet, Etelcalcetide)**: For secondary hyperparathyroidism in dialysis patients with elevated PTH despite other measures.
- **Active Vitamin D Analogs (Calcitriol, Paricalcitol, Doxercalciferol)**: May be used for PTH suppression; monitor for hypercalcemia and hyperphosphatemia.
- **Parathyroidectomy**: For refractory severe hyperparathyroidism.

### Vitamin D
- Correct 25(OH) vitamin D deficiency/insufficiency with cholecalciferol or ergocalciferol.

### Bone Biopsy
- Consider bone biopsy in CKD patients with unexplained fractures, bone pain, hypercalcemia, or before bisphosphonate use for osteoporosis.
